Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2018 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018

BOSTON, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
October 04, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline

-- MAA submission for both community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) -- -- EMA decision expected second half of 2019 -- BOSTON,...
October 03, 2018 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018

BOSTON, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
October 02, 2018 18:37 ET | Source: Paratek Pharmaceuticals

Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)

– Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) specifically designed to overcome tetracycline...
October 02, 2018 08:45 ET | Source: Paratek Pharmaceuticals

FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne

– To be launched in U.S. by Almirall SA – Paratek earns $12 million milestone payment BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical...
October 01, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
September 25, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018

BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be presented at...
September 04, 2018 16:30 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
August 29, 2018 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference

BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that it will present at Baird's 2018 Global Healthcare Conference on Wednesday, September 5 at...
August 08, 2018 14:20 ET | Source: Paratek Pharmaceuticals

FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline

-- Positive vote for both the skin infections and pneumonia indications -- -- FDA decision expected in early October 2018 -- BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....